View Ontology Report


Gefitinib belongs to a class of tyrosine kinase inhibitors (TKI) designed to compete with ATP for binding into the ATP binding pocket of mutated or over-expressed receptor and thus inhibit its tyrosine kinase activity and the signaling events downstream of it. Gefitinib along with erlotinib have been used to target epidermal growth factor receptor, Egfr. Gefitinib, presented here, was among the first and the most widely used TKI for use in the treatment of locally advanced or metastatic non-smal

Pathway Diagram:

Ariadne Genomics Inc. gefitinib other gefitinib metabolites O-desmethyl-gefitinib Egfr ---> gefitinib resistance gefitinib resistance Egfr ---- O-desmethyl-gefitinib ATP ---| Egfr ATP gefitinib pharmacokinetics pathway Egfr ---- gefitinib Egfr ---- other gefitinib metabolites epidermal growth factor/neuregulin signaling pathway ---| non-small cell lung cancer pathway epidermal growth factor/neuregulin signaling pathway ---| Carcinoma, Non-Small-Cell Lung Carcinoma, Non-Small-Cell Lung non-small cell lung cancer pathway Egfr epidermal growth factor/neuregulin signaling pathway Egfr ---| epidermal growth factor/neuregulin signaling pathway

Genes in Pathway:

show annotations for term's descendants       view all columns           Sort by:
gefitinib pharmacodynamics pathway term browser
Symbol Object Name JBrowse Chr Start Stop Reference
G Egfr epidermal growth factor receptor JBrowse link 14 99,919,485 100,104,136 RGD:5135288

Additional Elements in Pathway:

(includes Gene Groups, Small Molecules, Other Pathways..etc.)
Object TypePathway ObjectPathway Object Description
Small MoleculeATPadenosine triphosphate
DiseaseCarcinoma, Non-Small-Cell lungentry point to the respiratory disease portal
Pathwayepidermal growth factor/neuregulin signaling pathwayEpidermal growth factor/neuregulin signaling pathway plays a central role in the regulation of cell growth, differentiation, proliferation and survival
Small MoleculegefitinibIressa; ZD1839 (AstraZeneca Inc.)
Pathwaynon-small cell lung cancer pathwayLung cancer, a major cause of cancer mortality, has been assigned to two types: small-cell (SCLC) and non-small cell lung cancer (NSCLC). The first, an extremely aggressive form of cancer accounts for ~20% of cases while the second accounts for the remaining ~80%.
Small MoleculeO-desmethyl-gefitinibmain metabolite
Pathwaygefitinib pharmacokinetics pathwayThe pathway of processing - absorption, distribution, metabolism or elimination - of gefitinib

Pathway Gene Annotations

Disease Annotations Associated with Genes in the gefitinib pharmacodynamics pathway
Disease TermsGene Symbols
acute kidney failureEgfr
Acute Lung InjuryEgfr
adrenocortical carcinomaEgfr
Alzheimer's diseaseEgfr
Animal Mammary NeoplasmsEgfr
aortic valve diseaseEgfr
aortic valve stenosisEgfr
arteriovenous malformations of the brainEgfr
autistic disorderEgfr
autosomal recessive polycystic kidney diseaseEgfr
Bile Duct NeoplasmsEgfr
Brain NeoplasmsEgfr
breast cancerEgfr
breast carcinomaEgfr
Breast NeoplasmsEgfr
bronchiolo-alveolar adenocarcinomaEgfr
chronic obstructive pulmonary diseaseEgfr
Colonic NeoplasmsEgfr
colorectal cancerEgfr
Colorectal NeoplasmsEgfr
Cowden syndromeEgfr
Craniofacial AbnormalitiesEgfr
Diabetes Mellitus, Experimental Egfr
diabetic retinopathyEgfr
dilated cardiomyopathyEgfr
Disease ProgressionEgfr
Endometrioid CarcinomasEgfr
esophageal carcinomaEgfr
Esophageal NeoplasmsEgfr
esophagus squamous cell carcinomaEgfr
Experimental ArthritisEgfr
familial adenomatous polyposisEgfr
Gallbladder NeoplasmsEgfr
glioblastoma multiformeEgfr
Head and Neck NeoplasmsEgfr
head and neck squamous cell carcinomaEgfr
hepatocellular carcinomaEgfr
Hereditary Neoplastic SyndromesEgfr
Huntington's diseaseEgfr
Immediate HypersensitivityEgfr
Insulin ResistanceEgfr
Laryngeal NeoplasmsEgfr
Left Ventricular HypertrophyEgfr
lung adenocarcinomaEgfr
lung cancerEgfr
lung diseaseEgfr
Lung NeoplasmsEgfr
lung small cell carcinomaEgfr
lung squamous cell carcinomaEgfr
Lymphatic MetastasisEgfr
malignant gliomaEgfr
malignant mesotheliomaEgfr
Mammary Neoplasms, ExperimentalEgfr
Nasopharyngeal NeoplasmsEgfr
Neonatal Inflammatory Skin and Bowel Disease 2Egfr
Neoplasm InvasivenessEgfr
Neoplasm MetastasisEgfr
Neoplasm Recurrence, LocalEgfr
non-small cell lung carcinomaEgfr
Ovarian NeoplasmsEgfr
pancreatic cancerEgfr
Parkinson's diseaseEgfr
Parkinsonian DisordersEgfr
peptic esophagitisEgfr
Phyllodes TumorEgfr
pleomorphic xanthoastrocytomaEgfr
prostate cancerEgfr
Prostatic NeoplasmsEgfr
pulmonary fibrosisEgfr
pulmonary hypertensionEgfr
rectal neoplasmEgfr
renal cell carcinomaEgfr
Spinal Cord InjuriesEgfr
squamous cell carcinomaEgfr
Stomach NeoplasmsEgfr
Tobacco Use DisorderEgfr
tongue squamous cell carcinomaEgfr
transitional cell carcinomaEgfr
type 1 diabetes mellitusEgfr
type 2 diabetes mellitusEgfr
urinary bladder cancerEgfr
Uterine Cervical NeoplasmsEgfr
Pathway Annotations Associated with Genes in the gefitinib pharmacodynamics pathway
Phenotype Annotations Associated with Genes in the gefitinib pharmacodynamics pathway

References Associated with the gefitinib pharmacodynamics pathway:

Ontology Path Diagram:

paths to the root

Import into Pathway Studio: